OSE Immunotherapeutics SA
EPA:OSE.PA
8.98 (EUR) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 2.227 | 18.302 | 26.306 | 10.418 | 25.952 | 24.456 | 6.682 | 0.383 | 0.004 | 0 | 0 | 0 |
Cost of Revenue
| 0 | 0 | 0 | -0.001 | 0.008 | 0.004 | 0 | 0.016 | 0.013 | 0 | 0 | 0 |
Gross Profit
| 2.227 | 18.302 | 26.306 | 10.419 | 25.944 | 24.452 | 6.682 | 0.367 | -0.009 | 0 | 0 | 0 |
Gross Profit Ratio
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.958 | -2.25 | 0 | 0 | 0 |
Reseach & Development Expenses
| 24.216 | 29.903 | 33.962 | 27.842 | 25.091 | 19.69 | 18.567 | 8.031 | 2.939 | 2.133 | 0.154 | 1.309 |
General & Administrative Expenses
| 6.827 | 6.594 | 8.503 | 4.701 | 3.855 | 3.421 | 3.146 | 2.773 | 1.318 | 0.663 | 0.09 | 0.136 |
Selling & Marketing Expenses
| 0.068 | 0.046 | 0.068 | 0.064 | 1.585 | 0.977 | 1.505 | 0.679 | 1.857 | 0.135 | 0 | 0 |
SG&A
| 6.895 | 8.801 | 11.577 | 6.582 | 5.44 | 4.398 | 4.651 | 3.452 | 3.175 | 0.798 | 0.09 | 0.136 |
Other Expenses
| 8.052 | -0.078 | -0.134 | 0 | 0 | -0.027 | 0.002 | -2.324 | -0.008 | 0 | 0 | 0 |
Operating Expenses
| 31.111 | 38.782 | 45.673 | 34.424 | 30.531 | 19.598 | 19.388 | 17.176 | 5.591 | 2.837 | 0.25 | 1.445 |
Operating Income
| -32.355 | -24.037 | -21.973 | -24.736 | -5.061 | 4.847 | -12.625 | -0.567 | -5.42 | -2.815 | -0.25 | -1.445 |
Operating Income Ratio
| -14.529 | -1.313 | -0.835 | -2.374 | -0.195 | 0.198 | -1.889 | -1.48 | -1,355 | 0 | 0 | 0 |
Total Other Income Expenses Net
| 3.349 | 0.583 | 0.415 | 0.369 | 0.538 | -0.14 | -0.116 | 18.159 | -0.153 | -0.018 | 0 | 0.011 |
Income Before Tax
| -29.006 | -23.454 | -21.558 | -24.367 | -4.523 | 4.707 | -12.741 | 17.592 | -5.573 | -2.833 | -0.25 | -1.436 |
Income Before Tax Ratio
| -13.025 | -1.281 | -0.82 | -2.339 | -0.174 | 0.192 | -1.907 | 45.932 | -1,393.25 | 0 | 0 | 0 |
Income Tax Expense
| -6.003 | -5.694 | -4.708 | -7.812 | 0.129 | 0.783 | 2.238 | 3.074 | 0.011 | 0.002 | 0.25 | 1.745 |
Net Income
| -23.003 | -17.76 | -16.85 | -16.555 | -4.652 | 5.49 | -10.503 | 20.666 | -5.584 | -2.835 | -0.25 | -1.436 |
Net Income Ratio
| -10.329 | -0.97 | -0.641 | -1.589 | -0.179 | 0.224 | -1.572 | 53.958 | -1,396 | 0 | 0 | 0 |
EPS
| -1.18 | -0.96 | -0.93 | -1.06 | -0.31 | 0.35 | -0.73 | 1.65 | -0.59 | -0.36 | -0.033 | -0.18 |
EPS Diluted
| -1.18 | -0.96 | -0.93 | -1.06 | -0.31 | 0.35 | -0.73 | 1.52 | -0.59 | -0.36 | -0.033 | -0.18 |
EBITDA
| -28.884 | -20.48 | -19.367 | -24.006 | -4.579 | 4.963 | -12.502 | -0.46 | -5.321 | -0.018 | -0.25 | -1.436 |
EBITDA Ratio
| -12.97 | -1.119 | -0.736 | -2.304 | -0.176 | 0.203 | -1.871 | -1.201 | -1,330.25 | 0 | 0 | 0 |